These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 24998453)

  • 1. Primary systemic treatment and concomitant low dose radiotherapy for breast cancer: final results of a prospective phase II study.
    Nardone L; Diletto B; De Santis MC; D' Agostino GR; Belli P; Bufi E; Franceschini G; Mulé A; Sapino A; Terribile D; Valentini V
    Breast; 2014 Oct; 23(5):597-602. PubMed ID: 24998453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A feasibility study of neo-adjuvant low-dose fractionated radiotherapy with two different concurrent anthracycline-docetaxel schedules in stage IIA/B-IIIA breast cancer.
    Nardone L; Valentini V; Marino L; De Santis MC; Terribile D; Franceschini G; Balducci M; Mantini G; Mattiucci G; Mulè A; Belli P; Masetti R
    Tumori; 2012; 98(1):79-85. PubMed ID: 22495705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a role for salvage radiotherapy in locally advanced breast cancer refractory to neoadjuvant chemotherapy?
    Coelho RC; Da Silva FML; Do Carmo IML; Bonaccorsi BV; Hahn SM; Faroni LD
    Breast; 2017 Feb; 31():192-196. PubMed ID: 27889595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.
    Saracchini S; Foltran L; Tuccia F; Bassini A; Sulfaro S; Micheli E; Del Conte A; Bertola M; Gion M; Lorenzon M; Tumolo S
    Breast; 2013 Dec; 22(6):1101-7. PubMed ID: 24074879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.
    Bourgier C; Pessoa EL; Dunant A; Heymann S; Spielmann M; Uzan C; Mathieu MC; Arriagada R; Marsiglia H
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):690-5. PubMed ID: 21277101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term cosmesis after lumpectomy and brachytherapy in the management of carcinoma of the previously irradiated breast.
    Trombetta M; Julian TB; Werts DE; McWilliams W; Kim Y; Miften M; Parda D
    Am J Clin Oncol; 2009 Jun; 32(3):314-8. PubMed ID: 19451803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of radiotherapy and concurrent paclitaxel chemotherapy in breast-conserving treatment for node-positive breast cancer.
    Chen WC; Kim J; Kim E; Silverman P; Overmoyer B; Cooper BW; Anthony S; Shenk R; Leeming R; Hanks SH; Lyons JA
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):14-20. PubMed ID: 21035961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of chemoradiotherapy in patients with unresectable T4 breast tumors.
    Karasawa K; Saito M; Hirowatari H; Izawa H; Furuya T; Ozawa S; Ito K; Suzuki T; Mitsuhashi N
    Breast Cancer; 2013 Jul; 20(3):254-61. PubMed ID: 22274798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
    J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative taxane-based chemotherapy in a standardized protocol for locally advanced breast cancer.
    Chan A; Willsher PC; Hastrich DJ; Anderson J; Barham T; Latham B; Redfern A; VAN DER Schaaf A; Thomson J; Joseph D; Ingram D
    Asia Pac J Clin Oncol; 2012 Mar; 8(1):62-70. PubMed ID: 22369445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy and concomitant irradiation in inflammatory breast cancer.
    Tubiana-Mathieu N; Lejeune C; Bonnier P; Genet D; Adjadj DJ; Berda JF; Muracciole X; Delaby F; Clavere P; Benyoub A; Rhein B; Juin B; Piana L
    Anticancer Res; 2001; 21(4B):3061-7. PubMed ID: 11712811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
    Wenzel C; Bartsch R; Hussian D; Pluschnig U; Altorjai G; Zielinski CC; Lang A; Haid A; Jakesz R; Gnant M; Steger GG
    Breast Cancer Res Treat; 2007 Jul; 104(1):109-14. PubMed ID: 17061042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
    Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
    J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer.
    Cooper BW; Radivoyevitch T; Overmoyer BA; Shenk RR; Pham HT; Samuels JR; Parry MP; Silverman P
    Breast Cancer Res Treat; 2006 Jun; 97(3):311-8. PubMed ID: 16344915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer.
    Manga GP; Shahi PK; Ureña MM; Pereira RQ; Plaza MI; Peron YI; Val RG; Carrión JB; Cañón EP; Alfonso PG
    Breast Cancer; 2010 Jul; 17(3):205-11. PubMed ID: 19551465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similar long-term results of breast-conservation treatment for Stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: The University of Pennsylvania experience.
    Santiago RJ; Harris EE; Qin L; Hwang WT; Solin LJ
    Cancer; 2005 Jun; 103(12):2447-54. PubMed ID: 15887223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
    von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
    J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.